胰腺外科专题研究(Monographic Study of Pancreatic Surgery)

胰头十二指肠切除术联合替吉奥治疗胰腺癌的临床观察

Published at: 2015年第24卷第9期

李洪波 , 刘崇忠 2
1 山东肥城矿业中心医院 普通外科,山东 肥城 271608
2 山东大学齐鲁医院 普通外科,山东 济南 250012
通讯作者 崇忠 刘 Email: lczk1980@163.com
DOI: 10.3978/j.issn.1005-6947.10.3978/j.issn.1005-6947.2015.09.005
基金:

摘要

目的:探讨胰头十二指肠切除术联合替吉奥治疗胰腺癌的疗效。 方法:2008年2月—2011年6月间,58例I~II期胰腺癌患者行胰头十二指肠切除术后分别采取替吉奥 (32例,观察组)和吉西他滨(26例,对照组)辅助化疗,比较两组患者的近、远期疗效及化疗期间不良反应的发生情况。 结果:两组患者化疗后血清中各肿瘤标志物水平均明显较化疗前下降(均P<0.05),但两组间差异无统计学意义(均P>0.05);观察组患者总有效率明显高于对照组患者(37.50% vs. 30.77%,P<0.05);生存分析显示,观察组患者1、1.5、2年的总生存率明显高于对照组患者(均P<0.05);两组患者化疗期间不良反应均为I、II度,两组间不良反应发生率差异无统计学意义(P>0.05)。 结论:胰头十二指肠切除术加术后替吉奥辅助化疗治疗胰腺癌疗效确切,可有效延长患者术后生存期,且不良反应较轻,患者耐受良好。


Clinical observation of pancreaticoduodenectomy combined with tegafur/gimeracil/oteracil (S-1) adjuvant chemotherapy for pancreatic cancer

Abstract

Objective: To assess the efficacy of pancreaticoduodenectomy (PD) followed by tegafur/gimeracil/oteracil (S-1) adjuvant chemotherapy in treatment of pancreatic cancer. Methods: Between February 2008 and June 2011, 58 patients with stage I-II pancreatic cancer underwent PD followed by postoperative adjuvant chemotherapy with S-1 (32 cases, observational group) or gemcitabine (26 cases, control group). The short- and long- term efficacies as well as the incidence of adverse events during chemotherapy between the two groups of patients were compared. Results: The levels of serum tumor markers in both groups of patients were significantly decreased after chemotherapy compared with their levels before chemotherapy (all P<0.05), but showed no significant difference between the two groups (all P>0.05); the overall response rate in observational group was significantly higher than that in control group (37.50% vs. 30.77%, P<0.05); survival analysis showed that the 1-, 1.5- and 2-year overall survival rate in observational group were significantly higher than those in control group (all P<0.05); the adverse reactions in either group were grade I or II, and there was no significant difference in incidence of adverse reactions between the two groups (P>0.05). Conclusion: PD plus postoperative S-1 adjuvant chemotherapy for pancreatic cancer patients has proven efficacy, which may effectively prolong the postoperative survival time of the patients, with only mild adverse effects, and good tolerance.


comments powered by Disqus

全文

引用

引用本文: 洪波 李, 崇忠 刘. 胰头十二指肠切除术联合替吉奥治疗胰腺癌的临床观察[J]. 中国普通外科杂志, 2015, 24(9): 1232-1236.
Cite this article as: LI Hongbo, LIU Chongzhou . Clinical observation of pancreaticoduodenectomy combined with tegafur/gimeracil/oteracil (S-1) adjuvant chemotherapy for pancreatic cancer[J]. Chin J Gen Surg, 2015, 24(9): 1232-1236.